Editorial
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 28, 2006; 12(44): 7081-7086
Published online Nov 28, 2006. doi: 10.3748/wjg.v12.i44.7081
Table 1 Treatment response at the end of 24-wk follow-up after 24-wk therapy with IFN α2a 4.5 MIU tiw, 90 mcg/wk, 180 mcg/wk and 270 mcg/wk PEG IFN α2a (Adapted from W Cooksley et al[12])
Response at the end ofthe 24-wk follow-up4,5 MU IFN(n = 51)90 μg PEG IFN α2a(n = 49)180 μg PEG IFN α2a(n = 46)270 μg PEG IFN α2a(n = 48)
НВV DNA < 500 000 cp/mL13 (25%)21 (43%)18 (39%)13 (27%)
Loss of HBeAg13 (25%)18 (37%)16 (35%)14 (29%)
HBeAg seroconversion13 (25%)18 (37%)15 (33%)13 (27%)
Normal ALT13 (25%)21 (43%)16 (35%)15 (31%)
Combined response16 (12%)13 (27%)13 (28%)9 (19%)